Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway

Toxicology

Volumn 303, Issue , 2013, Pages 107-114

  Shi, Haitao ^a   Dong, Lei ^a   Jiang, Jiong ^a   Zhao, Juhui ^a   Zhao, Gang ^a   Dang, Xiaoyan ^a   Lu, Xiaolan ^a   Jia, Miao ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Chlorogenic acid; Liver fibrosis; Liver inflammation; TLR4

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN; CHLOROGENIC ACID; COLLAGEN TYPE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEPATITIS; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CARBON TETRACHLORIDE; CHLOROGENIC ACID; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; INFLAMMATION; LIVER; LIVER CIRRHOSIS; MALE; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

RATTUS;

EID: 84870689066     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.10.025     Document Type: Article

References (50)

1. Aoyama T., Paik Y.H., Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol. Res. Pract. 2010, Article ID:192543.
2. Aram G., Potter J.J., Liu X.P., Torbenson M.S., Mezey E. Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration. Hepatology 2008, 47:2051-2058.
3. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
4. Breinig M., Schirmacher P., Kern M.A. Cyclooxygenase-2 (COX-2) - a therapeutic target in liver cancer?. Curr. Pharm. Des. 2007, 13:3305-3315.
5. Brun P., Castagliuolo I., Pinzani M., Palu G., Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am. J. Physiol. Gastrointestinal Liver Physiol. 2005, 289:G571-G578.
6. Choi H.K., Pokharel Y.R., Lim S.C., Han H.K., Ryu C.S., Kim S.K., Kwak M.K., Kang K.W. Inhibition of liver fibrosis by solubilized coenzyme Q10: role of Nrf2 activation in inhibiting transforming growth factor-beta 1 expression. Toxicol. Appl. Pharmacol. 2009, 240:377-384.
7. Choi I., Kang H.S., Yang Y., Pyun K.H. IL-6 induces hepatic inflammation and collagen-synthesis in-vivo. Clin. Exp. Immunol. 1994, 95:530-535.
8. Choi Y., Jeon W.K., Hwang S.J., Kim B.I., Sohn C.I., Park D.I., Cho Y.K., Kim H.J., Park J.H. The role of the gut barrier function in the pathophysiology of viral liver cirrhosis. Hepato-Gastroenterol. 2011, 58:1244-1247.
9. Feng R.T., Lu Y.J., Bowman L.L., Qian Y., Castranova V., Ding M. Inhibition of activator protein-1, NF-kappa B, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J. Biol. Chem. 2005, 280:27888-27895.
10. Freedman N.D., Everhart J.E., Lindsay K.L., Ghany M.G., Curto T.M., Shiffman M.L., Lee W.M., Lok A.S., Di Bisceglie A.M., Bonkovsky H.L., Hoefs J.C., Dienstag J.L., Morishima C., Abnet C.C., Sinha R., Grp H.-C.T. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009, 50:1360-1369.
11. Friedman S.L. Liver fibrosis-from bench to bedside. J. Hepatol. 2003, 38:S38-S53.
12. Friedman S.L. Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. & Hepatol. 2010, 7:425-436.
13. Gressner O.A., Lahme B., Rehbein K., Siluschek M., Weiskirchen R., Gressner A.M. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPAR gamma and SMAD2/3-dependent pathways. J. Hepatol. 2008, 49:758-767.
14. Jagavelu K., Routray C., Shergill U., O'Hara S.P., Faubion W., Shah V.H. Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology 2010, 52:590-601.
15. Kao Y.H., Jawan B., Goto S., Hung C.T., Lin Y.C., Nakano T., Hsu L.W., Lai C.Y., Tai M.H., Chen C.L. High-mobility group box 1 protein activates hepatic stellate cells in vitro. Transplant. Proc. 2008, 40:2704-2705.
16. Kawada N. Evolution of hepatic fibrosis research. Hepatol. Res. 2011, 41:199-208.
17. Kayano K., Okita K. Does IL-6 regulate liver fibrosis/cirrhosis directly and indirectly?. J. Gastroenterol. 2000, 35:250-251.
18. Kim S.M., Park K.C., Kim H.G., Han S.J. Effect of selective cyclooxygenase-2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts. Hepatol. Res. 2008, 38:800-809.
19. Klatsky A.L., Armstrong M.A., Friedman G.D. Coffee, tea, and mortality. Ann. Epidemiol. 1993, 3:375-381.
20. Kono Y., Kobayashi K., Tagawa S., Adachi K., Ueda A., Sawa Y., Shibata H. Antioxidant activity of polyphenolics in diets - rate constants of reactions of chlorogenic acid and caffeic acid with reactive species of oxygen and nitrogen. BBA-Gen. Subjects 1997, 1335:335-342.
21. Lee K.J., Choi J.H., Jeong H.G. Hepatoprotective and antioxidant effects of the coffee diterpenes kahweol and cafestol on carbon tetrachloride-induced liver damage in mice. Food Chem. Toxicol. 2007, 45:2118-2125.
22. Lin R.S., Lee F.Y., Lee S.D., Tsai Y.T., Lin H.C., Lu R.H., Hsu W.C., Huang C.C., Wang S.S., Lo K.J. Endotoxemia in patients with chronic liver-diseases-relationship to severity of liver-diseases, presence of esophagel-varices, and hyperdynamic circulation. J. Hepatol. 1995, 22:165-172.
23. Lu Y.C., Yeh W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145-151.
24. Luckey S.W., Petersen D.R. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Exp. Mol. Pathol. 2001, 71:226-240.
25. Martinez O.N., Ricote G.C., Monzon C.G. Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases. Med. Clin. 2003, 121:743-748.
26. McKim S.E., Gabele E., Isayama F., Lambert J.C., Tucker L.M., Wheeler M.D., Connor H.D., Mason R.P., Doll M.A., Hein D.W., Arteel G.E. Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterol. 2003, 125:1834-1844.
27. O'Neill L.A. Therapeutic targeting of toll-like receptors for inflammatory and infectious diseases. Curr. Opin. Pharmacol. 2003, 3:396-403.
28. Olthof M.R., Hollman P.C.H., Buijsman M., van Amelsvoort J.M.M., Katan M.B. Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J. Nutr. 2003, 133:1806-1814.
29. Olthof M.R., Hollman P.C.H., Katan M.B. Chlorogenic acid and caffeic acid are absorbed in humans. J. Nutr. 2001, 131:66-71.
30. Paik Y.H., Schwabe R.F., Bataller R., Russo M.P., Jobin C., Brenner D.A. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatol. 2003, 37:1043-1055.
31. Parlesak A., Schafer C., Schutz T., Bode J.C., Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J. Hepatol. 2000, 32:742-747.
32. Pinzani M., Macias-Barragan J. Update on the pathophysiology of liver fibrosis. Expert Rev. Gastroenterol. Hepatol. 2010, 4:459-472.
33. Ruhl C.E., Everhart J.E. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterol. 2005, 129:1928-1936.
34. Ruwart M.J., Wilkinson K.F., Rush B.D., Vidmar T.J., Peters K.M., Henley K.S., Appelman H.D., Kim K.Y., Schuppan D., Hahn E.G. The integrated value of serum procollagen-III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat. Hepatology 1989, 10:801-806.
35. Sanz-Cameno P., Medina J., Garcia-Buey L., Garcia-Sanchez A., Borque M.J., Martin-Vilchez S., Gamallo C., Jones E.A., Moreno-Otero R. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J. Hepatol. 2002, 37:723-729.
36. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatol. 2008, 48:322-335.
37. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., Schwabe R.F. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007, 13:1324-1332.
38. Sekiya T., Adachi S., Kohu K., Yamada T., Higuchi O., Furukawa Y., Nakamura Y., Nakamura T., Tashiro K., Kuhara S., Ohwada S., Akiyama T. Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells. J. Biol. Chem. 2004, 279:6840-6846.
39. Sekiya T., Oda T., Matsuura K., Akiyama T. Transcriptional regulation of the TGF-beta pseudoreceptor BAMBI by TGF-beta signaling. Biochem. Biophys. Res. Commun. 2004, 320:680-684.
40. Shan J.H., Fu J., Zhao Z.H., Kong X.Q., Huang H., Luo L., Yin Z.M. Chlorogenic acid inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-kappa B and JNK/AP-1 activation. Int. Immunopharmacol. 2009, 9:1042-1048.
41. Shi H.Y., Dong L., Bai Y.H., Zhao J.H., Zhang Y., Zhang L. Chlorogenic acid against carbon tetrachloride-induced liver fibrosis in rats. Eur. J. Pharmacol. 2009, 623:119-124.
42. Shi H.Y., Dong L., Zhang Y., Bai Y.H., Zhao J.H., Zhang L. Protective effect of a coffee preparation (Nescafe pure (R)) against carbon tetrachloride-induced liver fibrosis in rats. Clin. Nutr. 2010, 29:399-405.
43. Shin J.W., Wang J.H., Kang J.K., Son C.G. Experimental evidence for the protective effects of coffee against liver fibrosis in SD rats. J. Sci. Food Agric. 2010, 90:450-455.
44. Simeonova P.P., Gallucci R.M., Hulderman T., Wilson R., Kommineni C., Rao M., Luster M.I. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol. Appl. Pharmacol. 2001, 177:112-120.
45. Thirunavukkarasu C., Watkins S.C., Gandhi C.R. Mechanisms of endotoxin-induced NO, IL-6, and TNF-alpha production in activated rat hepatic stellate cells: Role of p38 MAPK. Hepatology 2006, 44:389-398.
46. Tiggelman A.M.B., Boers W., Linthorst C., Sala M., Chamuleau R.A.F. Collagen-synthesis by human liver (myo)fibroblasts in culture-evidence for a regulatory role of IL-1-beta, IL-4, TGF-beta and IFN-gamma. J. Hepatol. 1995, 23:307-317.
47. Tverdal A., Skurtveit S. Coffee intake and mortality from liver cirrhosis. Ann. Epidemiol. 2003, 13:419-423.
48. Xu Y.X., Chen J.W., Yu X.A., Tao W.W., Jiang F.R., Yin Z.M., Liu C. Protective effects of chlorogenic acid on acute hepatotoxicity induced by lipopolysaccharide in mice. Inflamm. Res. 2010, 59:871-877.
49. Zhang X., Huang H., Yang T.T., Ye Y., Shan J.H., Yin Z.M., Luo L. Chlorogenic acid protects mice against lipopolysaccharide-induced acute lung injury. Injury-Int. J. Care Injured 2010, 41:746-752.
50. Zhu J.K., Mohan C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediat. Inflamm. 2010, Article ID:781235.